Actively Recruiting
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Led by Pathos AI, Inc. · Updated on 2026-04-24
252
Participants Needed
18
Research Sites
220 weeks
Total Duration
On this page
Sponsors
P
Pathos AI, Inc.
Lead Sponsor
D
Duke University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with Abiraterone acetate, Olaparib or 177Lu-PSMA-617 in patients with metastatic castration-resistant prostrate cancer (mCRPC).
CONDITIONS
Official Title
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Histologic confirmation of prostate adenocarcinoma
- Metastatic disease confirmed by imaging within 56 days prior to screening
You will not qualify if you...
- Evidence of small cell or neuroendocrine prostate cancer on most recent biopsy
- Liver metastases confirmed by biopsy or liver lesions larger than 1 cm on imaging
- Received chemotherapy, investigational agents, or anti-androgen therapy (enzalutamide, apalutamide, darolutamide) within 14 days before screening or within 5 half-lives
- Serious medical, psychiatric, psychological, familial, or geographical conditions that may interfere with participation or increase treatment risk
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
MemorialCare Orange Coast Medical Center
Fountain Valley, California, United States, 92708
Actively Recruiting
2
Cancer and Blood Research Center
Los Alamitos, California, United States, 90720
Actively Recruiting
3
University of Colorado Health
Aurora, Colorado, United States, 80045
Actively Recruiting
4
Mount Sinai Medical Center
Miami, Florida, United States, 33140
Actively Recruiting
5
Emory University Hospital
Atlanta, Georgia, United States, 30322
Actively Recruiting
6
University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
7
Community Health Network
Indianapolis, Indiana, United States, 46250
Actively Recruiting
8
Ochsner
Jefferson, Louisiana, United States, 70121
Actively Recruiting
9
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
Actively Recruiting
10
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Actively Recruiting
11
Siteman Cancer Center
St Louis, Missouri, United States, 63108
Actively Recruiting
12
Nebraska Cancer Specialists
Omaha, Nebraska, United States, 68130
Actively Recruiting
13
Duke University medical center
Durham, North Carolina, United States, 27710
Actively Recruiting
14
The Ohio State University
Columbus, Ohio, United States, 43210
Actively Recruiting
15
Taylor Cancer Research Center
Maumee, Ohio, United States, 43537
Actively Recruiting
16
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
Actively Recruiting
17
Oncology Consultants, P.A
Houston, Texas, United States, 77030
Actively Recruiting
18
NEXT Oncology - Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
S
Steve Kye, MD. MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here